Glatiramer acetate - Kinimmune
Alternative Names: KIN-102; KIN-101Latest Information Update: 28 Jan 2025
At a glance
- Originator King Abdulaziz University; University of Kansas Medical Center
- Developer Kinimmune; University of Kansas Medical Center
- Class Antineoplastics; Peptides; Polymers
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Basal cell cancer; Squamous cell cancer
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Basal-cell-cancer(Adjunctive treatment) in USA (Intratumoural, Injection)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Adjunctive treatment) in USA (Intratumoural, Injection)